Today: October 1, 2016, 7:14 pm

Iran pharmaceutical market: New market research published
The Pharmaceutical Market: Iran - a new market research report on 2014-03-13 14:41:02
We caution that our forecasts for the Iranian pharmaceutical market are at considerable risk due to runaway inflation and political risks. We also point out that the official exchange rate does not follow the trends in the black market, which further distorts market valuations. While our local currency forecast for the market´s development is broadly in line with the previous quarter´s figure, the value in US dollar terms will be considerably impacted by rising inflation, caused by the sanction induced currency crisis.

At the same time, we expect that the volume of pharmaceutical sales in the country will continue to be negatively impacted by the prevailing economic and political conditions. These have already resulted in shortages of certain medicines, on account of the inability of local stakeholders to actually pay for them, given that Iranian banks have been blacklisted. Therefore, despite the country´s demography-based long-term potential as a pharmaceutical market, its development clearly remains uncertain for the time being, and dependent on the eventual resolution of the crisis.

Headline Expenditure Projections

Pharmaceuticals: IRR52,127bn (US$1.04bn) in 2012 to IRR55,606bn (US$0.79bn) in 2013; +6.7% in local currency terms and -23.8% in US dollar terms. US dollar f orecast lowered considerably from Q4 12 due to r ampant inflation in Iran.

Healthcare: IRR298,573 (US$28.04bn) in 2012 to IRR387,824 (US$29.61bn) in 2013; -10.4% in local currency terms and +5.1% in US dollar terms. Local currency forecast lowered considerably from Q4 12 due changes in macroeconomic conditions.

Medical devices: IRR14,296bn (US$1.09bn) in 2012 to IRR11,862 (US$0.71); -17.0%% in local currency terms and -35.2% in US dollar terms. US dollar forecast lowered considerably from Q4 12 due to rampant inflation in Iran.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 519 Words
Related Articles
More From Finance
P2P lending platform Monexo partners with IDBI-Trusteeship [..]
For Immediate Release: 2nd September 2016 MUKESH BUBNA, CEO Monexo Fintech Pvt Limited P2P [..]
Day Trade to Win New September Class [..]
Sold Out? New Class Added – On September 6, 2016, is launching a brand new eight-week trading boot camp [..]
FTM (Forget The Market) Reopens 3 Shares [..]
Port Vila, Vanuatu, 28th July 2016 - Investment firm FTM today announced the reopening of three separate share options, projected [..]
Ex-Citibanker Launching Online P2P marketplace in India [..]
A study conducted by World Bank shows that MSMEs in India face an estimated credit gap of INR 20.9 trillion [..]
New Frontier Portfolios Top Morningstar Rankings
New Frontier’s global strategic portfolios topped the Global Balanced Strategic/All-Inclusive category of the latest Morningstar ETF [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.